- Home
- GDEN vs ADPT Comparison
GDEN vs ADPT Comparison
Compare GDEN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- ADPT
- Stock Information
- Founded
- GDEN 1998
- ADPT 2009
- Country
- GDEN United States
- ADPT United States
- Employees
- GDEN N/A
- ADPT N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDEN Consumer Discretionary
- ADPT Health Care
- Exchange
- GDEN Nasdaq
- ADPT Nasdaq
- Market Cap
- GDEN 961.7M
- ADPT 929.8M
- IPO Year
- GDEN 1999
- ADPT 2019
- Fundamental
- Price
- GDEN $31.12
- ADPT $6.39
- Analyst Decision
- GDEN Strong Buy
- ADPT Buy
- Analyst Count
- GDEN 6
- ADPT 4
- Target Price
- GDEN $37.33
- ADPT $6.75
- AVG Volume (30 Days)
- GDEN 315.0K
- ADPT 1.4M
- Earning Date
- GDEN 11-07-2024
- ADPT 02-12-2025
- Dividend Yield
- GDEN 3.21%
- ADPT N/A
- EPS Growth
- GDEN N/A
- ADPT N/A
- EPS
- GDEN 1.27
- ADPT N/A
- Revenue
- GDEN $733,305,000.00
- ADPT $177,282,000.00
- Revenue This Year
- GDEN N/A
- ADPT $6.48
- Revenue Next Year
- GDEN $2.28
- ADPT $18.84
- P/E Ratio
- GDEN $24.55
- ADPT N/A
- Revenue Growth
- GDEN N/A
- ADPT N/A
- 52 Week Low
- GDEN $27.42
- ADPT $2.28
- 52 Week High
- GDEN $40.85
- ADPT $7.07
- Technical
- Relative Strength Index (RSI)
- GDEN 36.06
- ADPT 56.16
- Support Level
- GDEN $32.62
- ADPT $5.81
- Resistance Level
- GDEN $33.59
- ADPT $6.93
- Average True Range (ATR)
- GDEN 1.03
- ADPT 0.50
- MACD
- GDEN -0.37
- ADPT -0.04
- Stochastic Oscillator
- GDEN 21.13
- ADPT 46.35
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).